Today: 28 February 2026
Subscribe
Browse Category

NYSE:PM 24 December 2025 - 13 February 2026

Philip Morris (PM) stock price slips today despite fresh target hikes as Zyn battle stays in view

Philip Morris (PM) stock price slips today despite fresh target hikes as Zyn battle stays in view

Philip Morris International shares fell 1.4% to $180.17 in Monday afternoon trading after a new debt shelf filing and recent earnings guidance. Investors focused on competition in nicotine pouches and upcoming U.S. economic data. The stock traded between $179.85 and $182.54, about 1.6% below its 52-week high. Several analysts raised their price targets following the company’s updated 2026 outlook.
9 February 2026
·
Philip Morris stock price watch: PM ends higher after 2026 outlook as Zyn rivalry heats up

Philip Morris stock price watch: PM ends higher after 2026 outlook as Zyn rivalry heats up

Philip Morris shares closed up 0.45% at $182.81 after posting Q4 adjusted earnings of $1.70 per share on $10.36 billion in revenue and forecasting 2026 EPS of $8.38–$8.53. Zyn nicotine pouch shipments rose over 19% to 196 million cans, but competition and promotional costs remain in focus. The stock traded between $178.00 and $186.55 on Friday. Next earnings are due April 21.
8 February 2026
·
Philip Morris stock price rises into weekend as PM investors brace for Feb. 6 earnings webcast

Philip Morris stock price rises into weekend as PM investors brace for Feb. 6 earnings webcast

Philip Morris International shares closed Friday up 0.87% at $179.44, trading between $175.14 and $180.09 on volume of 8.24 million. The company will report fourth-quarter and full-year earnings on Feb. 6, the same day as the U.S. jobs report and a wave of major corporate results. The S&P 500 fell 0.4% Friday after Donald Trump named Kevin Warsh as his pick for Federal Reserve chair.
31 January 2026
··
Philip Morris stock ticks up on Swedish Match plan filing as U.S. market softens

Philip Morris stock ticks up on Swedish Match plan filing as U.S. market softens

Philip Morris International shares rose 0.3% to $161.52 midday Monday after the company filed to register 500,000 shares for a Swedish Match North America employee profit-sharing plan. The filing, made on Form S-8, does not raise cash and relates to a program assumed in the 2022 Swedish Match acquisition. Other tobacco stocks were mixed. The broader market traded lower, with the S&P 500 ETF down 0.5%.
29 December 2025
··
Philip Morris International Stock (NYSE: PM) Update: Ex‑Dividend Drop Explained, ZYN Momentum in Focus, and Analyst Targets Ahead of Monday’s Open

Philip Morris International Stock (NYSE: PM) Update: Ex‑Dividend Drop Explained, ZYN Momentum in Focus, and Analyst Targets Ahead of Monday’s Open

Philip Morris International closed Friday at $161.05, down $1.59, after going ex-dividend for its $1.47 quarterly payout. The drop matched the dividend adjustment, not broader selling. Trading volume was thin as U.S. markets hovered near record highs. Recent PMI headlines focused on institutional position updates from SEC filings.
28 December 2025
··
Philip Morris International Inc. (PM) Stock: Ex‑Dividend Reset, Options Buzz, and What Investors Should Watch Before Monday’s Open

Philip Morris International Inc. (PM) Stock: Ex‑Dividend Reset, Options Buzz, and What Investors Should Watch Before Monday’s Open

Philip Morris International shares closed at $161.05 Friday, down about 1%, after trading ex-dividend for a $1.47 quarterly payout. The drop aligned with the ex-dividend date of Dec. 26, when new buyers no longer qualify for the dividend. U.S. markets were closed Saturday. Trading volume was light in the post-holiday session.
27 December 2025
··
Philip Morris International (PM) in Focus on Dec. 25, 2025: Dividend Deadline, ZYN FDA Catalyst, and 2026 Stock Forecasts

Philip Morris International (PM) in Focus on Dec. 25, 2025: Dividend Deadline, ZYN FDA Catalyst, and 2026 Stock Forecasts

Philip Morris International’s $1.47 quarterly dividend goes ex-dividend December 26, 2025, with payment set for January 14. Analysts remain split on valuation, with some calling shares undervalued and others warning of overvaluation. The FDA’s ongoing review of ZYN nicotine pouches draws close investor scrutiny. Debate continues over the company’s shift from tobacco to smoke-free products.
25 December 2025
1 2
Go toTop